Trial Profile
A phase I open-label, single-dose trial of methylphenidate extended- release (Cotempla XR-ODT) in children and adolescents with attention-deficit hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2018
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 04 Nov 2015 New trial record
- 30 Oct 2015 According to a Neos Therapeutics media release, results from this trial were presented at the American Academy of Child and Adolescent Psychiatry's (AACAP) 62nd Annual Meeting.
- 30 Oct 2015 Results were published in a Neos Therapeutics media release.